减少光动力疗法联合玻璃体内雷珠单抗治疗典型年龄相关性黄斑变性和息肉状脉络膜血管病变的两年疗效。

Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy.

机构信息

Department of Ophthalmology and Visual Science, Graduate School of Medicine, Osaka City University, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.

出版信息

Jpn J Ophthalmol. 2013 May;57(3):283-93. doi: 10.1007/s10384-013-0234-z. Epub 2013 Feb 15.

DOI:10.1007/s10384-013-0234-z

PMID:23413039

Abstract

PURPOSE

To report the 2-year results of reduced-fluence photodynamic therapy (RF-PDT) combined with intravitreal ranibizumab (IVR) for typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).

METHODS

Twenty-four previously untreated eyes of 23 AMD patients with decimal best-corrected visual acuity (BCVA) of less than 0.7 received the combined therapy, followed by retreatments as needed over the subsequent 2 years. When the BCVA was better than or equal to 0.7, only 3 monthly IVR injections were performed during the retreatment.

RESULTS

The BCVAs were maintained in 7 of 10 typical AMD eyes and in 13 of 14 PCV eyes at month 24. The mean BCVA improved in the PCV group (P < 0.05) but not in the typical AMD group. The central foveal thickness decreased in both groups (P < 0.01, P < 0.001). The mean numbers of the total PDT and IVR injections were 1.8 and 7.2 in the typical AMD group and 1.8 and 6.4 in the PCV group.

CONCLUSION

After RF-PDT combined therapy with administration of retreatments as needed that consisted of either 3 IVR injections alone or combined therapy, the BCVA was maintained in typical AMD and improved in PCV during a 2-year follow-up period.

摘要

目的

报告低强度光动力疗法（RF-PDT）联合玻璃体内雷珠单抗（IVR）治疗典型年龄相关性黄斑变性（AMD）和息肉样脉络膜血管病变（PCV）的 2 年结果。

方法

23 例 AMD 患者的 24 只未经治疗的眼，十进制最佳矫正视力（BCVA）低于 0.7，接受联合治疗，随后在接下来的 2 年内根据需要进行再治疗。当 BCVA 大于或等于 0.7 时，仅在再治疗期间进行 3 次每月 IVR 注射。

结果

在 24 个月时，10 只典型 AMD 眼中的 7 只和 14 只 PCV 眼中的 13 只保持了 BCVA。PCV 组的 BCVA 有所改善（P<0.05），但典型 AMD 组没有。两组的中央视网膜厚度均降低（P<0.01，P<0.001）。典型 AMD 组的总 PDT 和 IVR 注射次数分别为 1.8 和 7.2，PCV 组分别为 1.8 和 6.4。